A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions
Hodgkin Lymphoma
Interventions
DRUG

AFM 13

Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.

Trial Locations (3)

97080

University Hospital Würzburg, Würzburg

77030-2374

The University of Texas MD Anderson Cancer Center, Houston

50924 Köln

University Hosptial Cologne, Cologne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Affimed GmbH

INDUSTRY

NCT01221571 - A Study to Assess AFM13 in Patients With Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter